The Association for Research in Vision and Ophthalmology (ARVO) announced the launch of a new fellowship for early-career researchers. The Mallinckrodt Uveitis Research Fellowship, founded by Mallinckrodt Pharmaceuticals, will support early career investigators with a 1-year grant of $45,000 in their endeavor to investigate the impetus of uveitis or other inflammatory conditions in innovative ways.
“We are thrilled with Mallinckrodt’s initiative in funding this fellowship,” ARVO Foundation Board of Governors Chair Paul Sternberg, Jr., MD, FARVO, said in a news release. “This program will allow for the theories and drive of promising young researchers to come to fruition in the form of extraordinary results in the treatment of uveitis. We look forward to seeing what the future recipients accomplish.”
This fellowship will allow ARVO members working in a nonprofit or academic research center the freedom to explore causes and components of uveitis and similar disorders in novel ways. The hope is that the generation of promising preliminary results will evolve into powerful findings, making their way into impactful publications and stimulating further insights and advances in the ocular inflammation space.
“Inflammatory eye diseases are a broad category with several different known and unknown causes,” Tunde Otulana, MD, Chief Medical Officer of Mallinckrodt, said in the news release. “This fellowship aims to uncover the mechanisms behind conditions like uveitis, providing the vision community with vital information for additional research. We are honored to support the ARVO Foundation in fostering the next generation of answer seekers, treatment developers and cure finders.”
Applications for the fellowship will be open from July 1 to September 1, 2019.
For more information about the Mallinckrodt Uveitis Research Fellowship, visit ARVO’s website.